多发性硬化干扰素β治疗效果初步观察  

Preliminary Report on the Efficacy of Interferon β in 6 Chinese Patients with Multiple Sclerosis

作　　者：吴章薇[1] 张星虎[1] 艾青[1] 

机构地区：[1]首都医科大学附属北京天坛医院神经内科,北京100050

出　　处：《中国神经免疫学和神经病学杂志》2006年第6期331-334,共4页Chinese Journal of Neuroimmunology and Neurology

摘　　要：目的初步探讨干扰素（IFN-β）用于中国早期多发性硬化（MS）的疗效。方法对6例MS患者采用IFN-β治疗，并随访4～27个月。根据扩展的功能缺损状况量表评分（EDSS）、磁共振（MRI）T2加权病灶演变及持续缓解的时间，综合评价IFN-β的治疗疗效。结果6例患者随访期EDSS评分明显改善，T2W病灶负荷明显缩小。无复发者。结论IFN-β用于中国MS患者能改善其神经功能障碍．并减少复发。Objective To evaluate the efficacy of interferon β （IFN-β） in Chinese patients with muhiple sclerosis（MS） at early stage. Methods Six patients with MS were treated with IFN-β,and be followed up for 4- 27 months. The data of expanded disability status（EDSS）, T2-weighted lesion load on MRI and the remitting duration after treatment were analyzed together to evaluate the therapeutic efficacy of IFN-β. Results After treatment, EDSS scores of all 6 MS patients were decreased by one or more points. T2-weighted lesion burdens were also decreased. During follow-up, no one relapsed. Conclusions IFN-β could improve the neurological disability and reduce the relapse of MS.

关 键 词：多发性硬化 干扰素Β 治疗 

分 类 号：R744.51[医药卫生—神经病学与精神病学]